International Journal of
Reproductive Biomedicine
Mon, Feb 3, 2025
[Archive]
Volume 16, Issue 12 (December 2018)
IJRM 2018, 16(12): 767-774 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moradi F, Jahanian Sadatmahalleh S, Ziaei S. The effect of hormone replacement therapy
on cognitive function in postmenopausal
women: An RCT. IJRM 2018; 16 (12) :767-774
URL: http://ijrm.ir/article-1-1332-en.html
URL: http://ijrm.ir/article-1-1332-en.html
1- Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2- Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,Ziaei_sa@modares.ac.ir
2- Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,
Abstract: (3551 Views)
Background: During the reproductive age, the human brain becomes a target for gonadal steroid hormones. Estrogens influence neural function through effects on neurons and affects indirectly the oxidative stress, inflammation, the cerebral vascular and the immune system.
Objective: To evaluate the effect of the traditional hormone replacement therapy (HRT) on the cognitive function in postmenopausal women.
Materials and Methods: In this randomized clinical trial, 140 postmenopausal women, from November 2014 to February 2015, were included. Women were randomly divided into two groups. Each woman in the case group took traditional HRT (0.625mg conjugated equine estrogens+2.5mg medroxyprogesterone acetate daily) plus one Cal+D tablet (500 mg calcium+200 IU vitamin D) daily for four months. Women in the control group received only one Cal+D tablet (500 mg calcium+200 IU vitamin D) daily for four months period. The Montreal Cognitive Assessment (MoCA) and Green
Climacteric Scale (GCS) questionnaires filled out after the intervention and compared between the two groups.
Results: The mean points of the MoCA after the intervention indicate that all MoCA domains except for the orientation improved in the case group. There was a significant difference in the memory domain after the treatment between the two groups. MoCA domains and GCS were negatively correlated after the intervention (𝑟 = −0.235, 𝑝 =0.006).
Conclusion: The HRT has affected some of the MoCA factors. The effects of HRT on cognitive function should be studied in a large prospective study in a group of women in their early and late menopausal ages with periodic assessment of their cognitive function during these follow-up years.
Objective: To evaluate the effect of the traditional hormone replacement therapy (HRT) on the cognitive function in postmenopausal women.
Materials and Methods: In this randomized clinical trial, 140 postmenopausal women, from November 2014 to February 2015, were included. Women were randomly divided into two groups. Each woman in the case group took traditional HRT (0.625mg conjugated equine estrogens+2.5mg medroxyprogesterone acetate daily) plus one Cal+D tablet (500 mg calcium+200 IU vitamin D) daily for four months. Women in the control group received only one Cal+D tablet (500 mg calcium+200 IU vitamin D) daily for four months period. The Montreal Cognitive Assessment (MoCA) and Green
Climacteric Scale (GCS) questionnaires filled out after the intervention and compared between the two groups.
Results: The mean points of the MoCA after the intervention indicate that all MoCA domains except for the orientation improved in the case group. There was a significant difference in the memory domain after the treatment between the two groups. MoCA domains and GCS were negatively correlated after the intervention (𝑟 = −0.235, 𝑝 =0.006).
Conclusion: The HRT has affected some of the MoCA factors. The effects of HRT on cognitive function should be studied in a large prospective study in a group of women in their early and late menopausal ages with periodic assessment of their cognitive function during these follow-up years.
Type of Study: Original Article |
References
1. [1] Nguyen TV, Ducharme S, Karama S. Effects of sex steroids in the human brain. Mol Neurobiol 2017; 54: 7507–-7519. [DOI:10.1007/s12035-016-0198-3]
2. [2] Sturdee DW, Pines A, International Menopause Society Writing Group, Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hor- mone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302–320. [DOI:10.3109/13697137.2011.570590]
3. [3] Greendale GA, Wight RG, Huang MH, Avis N, Gold EB, Joffe H, et al. Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation. Am J Epidemiol 2010; 171: 1214–1224. [DOI:10.1093/aje/kwq067]
4. [4] Etgen T, Sander D, Bickel H, Forstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int 2011; 108: 743–-750.
5. [5] Karlamangla AS, Lachman ME, Han W, Huang M, Greendale GA. Evidence for cognitive aging in midlife women: study of women's health across the nation. PLoS One 2017; 12: e0169008. [DOI:10.1371/journal.pone.0169008]
6. [6] Pimenta F, Leal I, Maroco J, Ramos C. Menopausal symp- toms: do life events predict severity of symptoms in peri- and post-menopause? Maturitas 2012; 72: 324–-331. [DOI:10.1016/j.maturitas.2012.04.006]
7. [7] Goveas JS, Espeland MA, Hogan P, Dotson V, Tarima S, Coker LH, et al. Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study. J Affect Disord 2011; 132: 275–-284. [DOI:10.1016/j.jad.2011.01.020]
8. [8] Goveas JS, Espeland MA, Woods NF, Wassertheil-Smoller S, Kotchen JM. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 2011; 59: 57–-66. [DOI:10.1111/j.1532-5415.2010.03233.x]
9. [9] Rapp SR, Legault C, Henderson VW, Brunner RL, Masaki K, Jones B, et al. Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study. Alzheimer Dis Assoc Disord 2010; 24: 248–-255. [DOI:10.1097/WAD.0b013e3181d715d5]
10. [10] Mitchell ES, Woods NF. Cognitive symptoms during the menopausal transition and early postmenopause. Climac- teric 2011; 14: 252–-261.
11. [11] Etgen T, Bickel H, Forstl H. Metabolic and endocrine factors in mild cognitive impairment. Ageing Res Rev 2010; 9: 280– [DOI:10.1016/j.arr.2010.01.003]
12. [12] Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric 2012; 15: 256–-262. [DOI:10.3109/13697137.2012.660613]
13. [13] Scali J, Ryan J, Carriere I, Dartigues JF, Tavernier B, Ritchie K, et al. A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study. J Clin Psychiatry 2010; 71: 1673–-1679. [DOI:10.4088/JCP.09m05188blu]
14. [14] Ratka A. Menopausal hot flashes and development of cognitive impairment. Ann N Y Acad Sci 2005; 1052: 11–-26. [DOI:10.1196/annals.1347.002]
15. [15] Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assess- ment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–-699. [DOI:10.1111/j.1532-5415.2005.53221.x]
16. [16] Emsaki G, Molavi H, Chitsaz A, Movahed Abtahi M, Asgari K. [Psychometric properties of the montreal cognitive assessment (MoCA) in parkinson's disease patients in Isfahan]. J Isfahan Med Sch 2011; 29: 1391–-1400 (in Persian).
17. [17] Greene JG. A factor analytic study of climacteric symp- toms. J Psychosom Res 1976; 20: 425–-430. [DOI:10.1016/0022-3999(76)90005-2]
18. [18] Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. Cognitive effects of estradiol
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
